Acute myeloid leukemia is a rapidly progressing cancer of the blood-forming cells in the bone marrow. It develops when immature myeloid cells acquire abnormal changes, multiply uncontrollably and interfere with the production of healthy red blood cells, white blood cells and platelets.
AML does not usually form a single tumour. Leukemia cells are generally present in the bone marrow and blood and may sometimes involve the spleen, liver, lymph nodes, skin, gums, central nervous system or other tissues.
AML includes several biologically distinct subtypes defined by cell appearance, chromosome changes, gene mutations and the clinical setting in which the disease developed. Accurate classification is important because the subtype can influence prognosis, treatment selection and the need for stem-cell transplantation.
At Apollo Cancer Centres, AML care is planned by a multidisciplinary team that may include hemato-oncologists, pediatric oncologists, stem-cell transplant specialists, pathologists, molecular-diagnostics specialists, infectious-disease physicians, critical-care teams and supportive-care professionals.
Risk Factors for Acute Myeloid Leukemia
Acute Myeloid Leukemia Signs and Symptoms
How Acute Myeloid Leukemia Is Diagnosed
AML is usually suspected after a complete blood count or peripheral blood smear identifies abnormal blood-cell levels or circulating blast cells. A bone-marrow examination is generally required to confirm the diagnosis and obtain material for detailed immunophenotypic, chromosome and molecular testing.
Some recurrent genetic abnormalities can establish an AML diagnosis even when the blast percentage is below the threshold traditionally used for other subtypes. The results must also distinguish AML from acute lymphoblastic leukemia, mixed-phenotype acute leukemia, myelodysplastic syndromes and other myeloid disorders. Accurate classification should be completed promptly so that treatment can be selected according to the disease biology and the patient's clinical condition.
Chest X-ray
A chest X-ray may be performed when the patient has fever, cough, breathlessness or suspected pneumonia. It can identify lung infection, fluid around the lungs or another cause of respiratory symptoms. A baseline chest X-ray may also be obtained before intensive treatment in selected patients. However, a normal X-ray does not exclude an early infection in someone with a weakened immune system. CT may be required when symptoms persist or more detailed assessment is needed.
CT Scan
CT may be used to investigate fever, abdominal pain, breathing difficulty, neurological symptoms or suspected internal bleeding. Chest CT can detect fungal or bacterial lung infection more sensitively than a routine X-ray. Abdominal and pelvic CT may assess the liver, spleen, lymph nodes, bowel or another source of infection. It can also evaluate a suspected myeloid sarcoma, which is a mass of leukemia cells outside the bone marrow. Intravenous contrast is used according to kidney function and the clinical question.
MRI
MRI provides detailed assessment of the brain, spine, nerves, soft tissues and bone marrow without ionising radiation. It may be performed for persistent headache, weakness, seizures, spinal symptoms or suspected central nervous system involvement. MRI can also evaluate an extramedullary mass or possible myeloid sarcoma. It does not replace cerebrospinal-fluid examination when microscopic central nervous system disease is suspected. The urgency of imaging depends on the patient's neurological condition and clinical stability.
Ultrasound
Ultrasound may evaluate an enlarged liver or spleen, abdominal symptoms, swollen lymph nodes or a suspected collection of fluid. It may also assess blood flow when a catheter-related clot is suspected. Ultrasound is portable and does not involve radiation, making it useful in acutely unwell patients. It is not routinely needed to diagnose AML. Suspicious findings may require further imaging or tissue sampling.
PET-CT Scan
PET-CT is not routinely used to diagnose or monitor typical bone-marrow AML. It may be considered when myeloid sarcoma or another extramedullary site is suspected. Increased tracer uptake can also occur with infection or inflammation and therefore requires careful interpretation. Bone-marrow examination and molecular or MRD testing remain more appropriate for assessing systemic response. PET-CT may occasionally help define the extent of an extramedullary lesion or select a biopsy site.
Echocardiogram
An echocardiogram assesses heart structure and function before treatment that may include an anthracycline medicine. It establishes a baseline and can help determine whether standard intensive chemotherapy is appropriate. An electrocardiogram may also be performed, particularly when medicines can affect heart rhythm. Pre-existing cardiac disease may influence drug selection, dose or monitoring. Cardiac assessment may be repeated if symptoms or treatment-related concerns develop.
Bone-Marrow Aspiration
Bone-marrow aspiration removes liquid marrow, usually from the back of the hip bone. The sample is examined to determine the percentage, appearance and characteristics of blast cells. It also provides cells for flow cytometry, chromosome analysis, fluorescence in-situ hybridisation and molecular testing. These studies establish the AML subtype and identify findings that may influence prognosis or targeted treatment. Repeat aspiration may be used to assess remission and measurable residual disease.
Bone-Marrow Biopsy
A bone-marrow biopsy removes a small core of bone and marrow, usually during the same procedure as aspiration. It shows marrow cellularity, architecture, fibrosis and the pattern of leukemia-cell infiltration. Biopsy is especially useful when aspiration produces insufficient material or a "dry tap." Immunohistochemistry can help confirm myeloid differentiation and identify specific cell populations. Temporary soreness or bruising may occur, while serious bleeding or infection is uncommon.
Lumbar Puncture
Lumbar puncture is not routinely required for every patient with AML because central nervous system involvement is uncommon. It may be performed when the patient has neurological symptoms, certain high-risk features or known extramedullary disease. Cerebrospinal fluid is collected from the lower back and examined for leukemia cells. Intrathecal chemotherapy may be administered during the procedure when central nervous system treatment is required. The timing considers the platelet count, bleeding risk and presence of circulating blasts.
Biopsy of an Extramedullary Mass
AML may occasionally form a tumour outside the bone marrow called myeloid sarcoma. A tissue biopsy may be needed when a mass is the first or predominant manifestation of disease. The specimen undergoes histology, immunohistochemistry and molecular testing to distinguish myeloid sarcoma from lymphoma or another cancer. Bone-marrow and blood evaluation remain necessary because apparently localised disease may be part of systemic AML. Treatment generally follows systemic AML principles.
Laboratory
Blood and bone-marrow samples undergo detailed morphological, immunophenotypic, cytogenetic and molecular assessment. Testing may include:
Complete blood count: Measures red blood cells, white blood cells and platelets and may show anemia, thrombocytopenia, neutropenia or an abnormal white-cell count.
Peripheral blood smear: Examines blood-cell appearance and may identify circulating myeloblasts or Auer rods.
Bone-marrow morphology: Determines the proportion and appearance of blasts and evaluates normal blood-cell production.
Cytochemistry: Selected stains may help demonstrate myeloid differentiation when required.
Flow cytometry: Identifies proteins expressed by abnormal cells and distinguishes AML from ALL, mixed-phenotype leukemia and other marrow disorders.
Chromosome analysis: Detects numerical or structural chromosome abnormalities that contribute to classification and risk assessment.
FISH testing: Rapidly identifies selected rearrangements or chromosome changes when an urgent or targeted result is needed.
FLT3 testing: Identifies FLT3 mutations that may make the patient eligible for FLT3-targeted treatment.
NPM1 testing: Helps define disease subtype and risk and may provide a molecular marker for response monitoring.
CEBPA testing: Identifies specific mutations associated with a distinct AML subtype and prognostic group.
IDH1 and IDH2 testing: May identify eligibility for an IDH inhibitor in appropriate clinical settings.
Coagulation testing: PT, aPTT, fibrinogen and D-dimer assess unexplained bleeding, abnormal clotting or treatment-related complications.
Tumour-lysis tests: Uric acid, potassium, phosphate, calcium, creatinine and LDH assess tumour-lysis risk and organ effects.
Infection screening: May include hepatitis B, hepatitis C, HIV and other tests before immunosuppressive therapy.
HLA typing: Assesses potential compatibility with related or unrelated stem-cell donors when transplantation may be required.
Germline genetic testing: May be recommended when age, family history or molecular findings suggest an inherited predisposition to myeloid cancer.
AML classification should integrate morphology, immunophenotype, genetic abnormalities and clinical history. Molecular results may affect diagnosis, prognostic grouping, treatment selection, transplant planning and the method used to monitor residual disease.
AML is not usually staged from I to IV because leukemia cells are present in the blood-forming system from the outset. Instead, patients are classified according to disease biology, genetic risk, previous disorders or treatment, and response to therapy.
Risk assessment may consider:
Age and general health
White-cell count and clinical condition at presentation
Whether AML developed after a previous blood disorder
Previous chemotherapy or radiation exposure
Chromosome abnormalities
Gene mutations and molecular subtype
Presence of extramedullary or central nervous system disease
Response to induction treatment
Measurable residual disease after treatment
Whether the disease is newly diagnosed, refractory or relapsed
Duration of the first remission
Suitability for intensive treatment or stem-cell transplantation
The European LeukemiaNet system classifies adult AML into favourable-, intermediate- and adverse-risk groups using chromosome and molecular findings. These categories help estimate relapse risk and guide decisions about consolidation and stem-cell transplantation.
Favourable-risk disease includes selected core-binding-factor leukemias and AML with certain NPM1 or CEBPA alterations. Adverse-risk disease includes particular chromosome abnormalities, TP53 alterations and defined myelodysplasia-related genetic changes. Findings not assigned to either category may fall into the intermediate-risk group.
Genetic risk is not interpreted in isolation. Age, general health, treatment received and MRD response can substantially affect prognosis. Risk may be reassessed when additional molecular results become available or if the disease returns.
How Acute Myeloid Leukemia Is Treated
Intensive Induction Therapy
Intensive induction aims to achieve complete remission by reducing leukemia cells and restoring normal blood-cell production. A commonly used approach combines cytarabine given over several days with an anthracycline medicine. Other medicines may be added according to the disease subtype, genetic findings and treatment protocol.
Patients with a suitable FLT3 mutation may receive a FLT3 inhibitor with induction therapy. Gemtuzumab ozogamicin, an antibody–drug conjugate targeting CD33, may be incorporated for selected patients, particularly those with favourable-risk core-binding-factor AML. Clinical trials may offer additional targeted or immune-based combinations.
Intensive induction causes profound temporary bone-marrow suppression. Patients require close monitoring for infection, bleeding, tumour lysis, organ toxicity and other complications. Bone-marrow assessment is performed at protocol-defined time points to determine response and plan further treatment.
Lower-Intensity Treatment
Older adults and patients with significant medical conditions may not be suitable for intensive induction. Lower-intensity treatment often combines a hypomethylating agent, such as azacitidine or decitabine, with venetoclax. Venetoclax targets BCL-2, a protein that helps leukemia cells survive.
These regimens can produce deep remissions but may still cause prolonged neutropenia, infection and low platelet counts. Treatment schedules and doses may require adjustment according to marrow response, blood-count recovery and interactions with antifungal medicines. Bone-marrow examinations help distinguish persistent leukemia from treatment-related marrow suppression.
Other options may include low-dose cytarabine, a hypomethylating agent alone or targeted therapy when an appropriate mutation is present. Selection considers the likelihood of benefit, treatment burden, quality of life and the patient's goals.
Consolidation Therapy
Consolidation is given after remission to eliminate residual leukemia cells and reduce the risk of relapse. Patients with favourable-risk disease may receive several cycles of high- or intermediate-dose cytarabine-based chemotherapy. The number and intensity of cycles depend on age, subtype, genetic findings and treatment tolerance.
Patients with intermediate- or adverse-risk disease may be considered for allogeneic stem-cell transplantation during the first remission. MRD results are increasingly used to refine this decision. Persistent MRD can indicate a higher relapse risk even when standard remission criteria have been met.
Consolidation can cause infection, bleeding, neurological effects, eye irritation and prolonged blood-count suppression. Patients are monitored closely between cycles, and treatment is delayed or adjusted when recovery is inadequate.
Targeted Treatment
Targeted medicines are selected according to mutations or proteins identified in the leukemia cells. FLT3 inhibitors may be used during frontline treatment, maintenance in selected settings or treatment of relapsed FLT3-mutated AML. The exact medicine and combination depend on disease status and the treatment protocol.
IDH1 or IDH2 inhibitors may be used for selected patients whose leukemia carries the corresponding mutation. These medicines may cause differentiation syndrome and require appropriate monitoring. Gemtuzumab ozogamicin targets CD33 and may be incorporated into treatment for eligible patients.
Targeted treatments are not interchangeable across all AML subtypes. Molecular testing at diagnosis and relapse is important because the genetic profile can change over time. Treatment selection also considers previous therapy, organ function, medicine interactions and transplant plans.
Maintenance Therapy
Maintenance treatment may be considered after remission and consolidation for selected patients who are not proceeding immediately to stem-cell transplantation. Oral azacitidine may be used in certain adults who achieved remission after intensive chemotherapy but cannot complete further intensive curative treatment.
Maintenance is intended to prolong remission rather than replace adequate induction and consolidation. It is given in repeated cycles and continued while it remains beneficial and tolerable. Blood counts and organ function are monitored, and doses may be adjusted for toxicity.
The suitability of maintenance depends on the previous treatment, disease risk, MRD findings, transplant plan and the patient's general health. Not every patient with AML requires maintenance therapy.
Treatment of Relapsed or Refractory AML
Refractory AML does not enter remission with initial treatment, while relapsed AML returns after remission. Repeat molecular testing is important because new targetable abnormalities may be identified. Treatment depends on the duration of the first remission, previous medicines, genetic findings, age, organ function and transplant eligibility.
Options may include salvage chemotherapy, venetoclax-based treatment, a FLT3 inhibitor, an IDH inhibitor, gemtuzumab ozogamicin or a clinical trial. The objective is often to achieve another remission and proceed to allogeneic stem-cell transplantation when appropriate. Some patients may receive lower-intensity disease control and supportive care based on their health and preferences.
Relapse after transplantation may be treated using targeted therapy, chemotherapy, reduced immunosuppression, donor lymphocyte infusion or another transplant-related strategy. Treatment is individualised because relapsed AML varies widely in biology and clinical behaviour.
Allogeneic Stem-Cell Transplantation
Allogeneic hematopoietic stem-cell transplantation replaces the patient's blood-forming system with stem cells from a compatible donor. It is commonly considered for eligible patients with intermediate- or adverse-risk AML, persistent MRD, primary refractory disease or AML that has relapsed and returned to remission.
Before transplantation, conditioning chemotherapy, with or without radiation, reduces leukemia and suppresses the immune system. Donor cells can produce a graft-versus-leukemia effect, in which the new immune system attacks residual cancer cells. Donors may be matched siblings, matched or mismatched unrelated individuals, haploidentical relatives or cord-blood sources.
Risks include severe infection, organ toxicity, infertility, graft failure, graft-versus-host disease and treatment-related mortality. The decision balances these risks against the probability of relapse without transplantation. Age, health, disease risk, MRD, donor availability and patient preferences are considered.
Autologous Stem-Cell Transplantation
Autologous transplantation uses the patient's own previously collected stem cells. It does not provide a graft-versus-leukemia effect and is much less commonly used in AML than allogeneic transplantation. It may be considered for a small, carefully selected group of patients when an allogeneic donor is unavailable or unsuitable.
The procedure requires the patient to be in a deep remission without detectable contamination of the collected cells. Relapse remains an important concern because the reinfused immune system does not attack leukemia in the same way as donor cells. Its role varies between treatment programmes and is not appropriate for most patients.
Radiation for Myeloid Sarcoma
Radiation may be used when a myeloid sarcoma causes pain, nerve compression, impaired organ function or another urgent local problem. It may also be considered when a local mass persists after systemic treatment. Radiation can reduce the mass and improve local control, but it does not replace systemic AML therapy.
The dose and treatment area depend on the site, size, symptoms and previous treatment. Nearby organs are protected as much as possible during planning. Surgery may occasionally be required to obtain tissue or relieve compression, but chemotherapy remains the principal treatment.
Central Nervous System Radiation
Central nervous system involvement is uncommon in AML. Treatment usually includes intrathecal chemotherapy and systemic therapy capable of treating leukemia throughout the body. Cranial or craniospinal radiation may be considered for persistent, recurrent or bulky disease in selected patients.
The decision considers age, neurological symptoms, previous treatment and potential long-term effects. Radiation is planned carefully to limit exposure to the brain, eyes, spinal cord and endocrine structures. It is not used routinely as preventive treatment for most patients with AML.
Total-Body Irradiation
Total-body irradiation may be incorporated into the conditioning regimen before allogeneic stem-cell transplantation. It treats leukemia cells throughout the body and suppresses the immune system before donor-cell infusion. Many AML transplants instead use chemotherapy-only conditioning.
The conditioning approach depends on age, organ function, disease status and transplant protocol. Potential effects include fatigue, mouth soreness, infertility, cataracts, endocrine problems and an increased risk of later cancers. Long-term follow-up is required after transplantation.
Palliative Radiation Therapy
Short-course radiation may relieve pain, bleeding, nerve compression or other symptoms caused by a localised leukemia deposit. It is generally used alongside systemic treatment or supportive care. The schedule is selected to provide symptom relief while limiting treatment burden.
Response may develop during treatment or over the following weeks. Pain medicines and other symptom-directed measures continue alongside radiation. Palliative radiation does not treat leukemia throughout the body.
AML can be cured in some patients, but outcomes vary considerably. Prognosis depends on the biological characteristics of the leukemia, patient health and depth of response to treatment rather than on anatomical stage.
Follow-up includes clinical assessment, blood counts and bone-marrow examinations when indicated. Molecular monitoring may be used for subtypes with a suitable marker, such as NPM1-mutated AML. Survivorship care addresses heart health, infections, immunity, fertility, emotional well-being and late effects of chemotherapy or transplantation.
Why Choose ACC for Acute Myeloid Leukemia Treatment